Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR [SLI 381]) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR [SLI 381]) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 18 Apr 2015

At a glance

  • Drugs Mixed amfetamine salts (Primary)
  • Indications Attention-deficit hyperactivity disorder; Cocaine abuse
  • Focus Therapeutic Use
  • Acronyms CAMP
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 28 Jan 2013 Planned end date changed from 1 Jan 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 14 Sep 2011 Planned end date changed from 1 Jan 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top